Standout Papers

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for ... 2010 2026 2015 2020 490
  1. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010)
    Martin Reck, Joachim von Pawel et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 13 from Science/Nature 76 standout
Sub-graph 1 of 19

Citing Papers

Cancer Statistics, 2021
2021 Standout
Physical traits of cancer
2020 StandoutScience
5 intermediate papers

Works of C. Manegold being referenced

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010 Standout
9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)
2009
and 1 more

Author Peers

Author Last Decade Papers Cites
C. Manegold 1486 1121 397 82 2.4k
Domenico Galetta 1474 1312 361 174 2.7k
Jonathan E. Dowell 1301 1095 446 86 2.4k
Matthew J. Bott 1924 882 497 100 2.8k
Marjorie G. Zauderer 1161 741 356 99 2.2k
Stein Sundstrøm 1300 1422 508 78 2.5k
Meghan J. Mooradian 1145 1702 454 67 2.5k
Panos Fidias 1811 1673 914 58 2.9k
Yang Yao 1053 1138 697 126 2.4k
Gavin Wright 2035 1250 451 126 2.9k
Masaru Narabayashi 870 1003 328 94 2.5k

All Works

Loading papers...

Rankless by CCL
2026